Sionna Therapeutics (NASDAQ:SION) Director Sells $2,664,412.86 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 59,767 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $44.58, for a total transaction of $2,664,412.86. Following the transaction, the director owned 2,856,461 shares of the company’s stock, valued at approximately $127,341,031.38. This trade represents a 2.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Orbimed Advisors Llc also recently made the following trade(s):

• On Monday, May 11th, Orbimed Advisors Llc sold 184,639 shares of Sionna Therapeutics stock. The shares were sold at an average price of $46.22, for a total transaction of $8,534,014.58.
• On Thursday, May 7th, Orbimed Advisors Llc sold 48,546 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.61, for a total transaction of $2,165,637.06.
• On Saturday, April 18th, Orbimed Advisors Llc sold 2,948 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.52, for a total transaction of $131,244.96.
• On Friday, April 17th, Orbimed Advisors Llc sold 52,397 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.68, for a total transaction of $2,341,097.96.
• On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The shares were sold at an average price of $45.34, for a total transaction of $10,287,918.04.
• On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.64, for a total transaction of $10,528,924.32.
• On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.51, for a total transaction of $2,128,201.14.

Sionna Therapeutics Stock Performance

NASDAQ:SION opened at $43.12 on Thursday. The stock has a market capitalization of $1.95 billion, a P/E ratio of -22.34 and a beta of 1.35. The company has a 50 day moving average price of $39.11 and a 200 day moving average price of $39.51. Sionna Therapeutics, Inc. has a fifty-two week low of $11.77 and a fifty-two week high of $48.44.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). Research analysts forecast that Sionna Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sionna Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Deutsche Bank AG raised its holdings in shares of Sionna Therapeutics by 4.5% in the 4th quarter. Deutsche Bank AG now owns 10,029 shares of the company’s stock valued at $413,000 after purchasing an additional 433 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Sionna Therapeutics by 8.8% in the 3rd quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock valued at $192,000 after purchasing an additional 529 shares in the last quarter. MetLife Investment Management LLC raised its holdings in shares of Sionna Therapeutics by 6.6% in the 4th quarter. MetLife Investment Management LLC now owns 8,565 shares of the company’s stock valued at $352,000 after purchasing an additional 532 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Sionna Therapeutics by 35.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock valued at $70,000 after purchasing an additional 619 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Sionna Therapeutics in the 4th quarter valued at $36,000.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on SION shares. UBS Group reaffirmed a “buy” rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Guggenheim increased their price objective on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Citigroup assumed coverage on shares of Sionna Therapeutics in a research report on Tuesday, February 24th. They set an “outperform” rating for the company. Wedbush assumed coverage on shares of Sionna Therapeutics in a report on Tuesday, May 5th. They set an “outperform” rating and a $53.00 target price on the stock. Finally, BTIG Research reiterated a “buy” rating and set a $58.00 target price on shares of Sionna Therapeutics in a report on Wednesday. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Sionna Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $53.00.

More Sionna Therapeutics News

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating on Sionna Therapeutics and kept a $58 price target, implying meaningful upside from recent trading levels and reinforcing optimism around the company’s clinical pipeline. Article Title
• Positive Sentiment: Sionna Therapeutics said management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 20, which can give investors a fresh update on the company’s cystic fibrosis programs and keep attention on the story. Article Title
• Neutral Sentiment: In its first-quarter update, the company said enrollment is complete in the PreciSION CF Phase 2a trial for SION-719 and that topline data is expected in summer 2026, while the SION-451 Phase 1 study is also on track. It also reported a strong cash balance of about $289.9 million, supporting operations into 2028. Article Title
• Negative Sentiment: Sionna reported a first-quarter loss of $0.60 per share, wider than the expected $0.52 loss, which may weigh on sentiment even though the company remains pre-revenue and focused on clinical development. Article Title
• Negative Sentiment: Director OrbiMed Advisors and director Peter A. Thompson disclosed several large share sales in recent days. The transactions were made under pre-arranged 10b5-1 plans, but the size of the selling can still pressure investor sentiment. Article Title

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.